Nanovibronix (FEED) Competitors

$1.23 +0.09 (+7.89%)

Closing price 04:00 PM Eastern

Extended Trading

$1.20 -0.02 (-2.03%)

As of 07:48 PM Eastern

FEED vs. IRIX, ZJYL, SURG, ICU, and OSRH

Should you be buying Nanovibronix stock or one of its competitors? The main competitors of Nanovibronix include IRIDEX (IRIX), Jin Medical International (ZJYL), SurgePays (SURG), SeaStar Medical (ICU), and OSR (OSRH). These companies are all part of the "medical equipment" industry.

How does Nanovibronix compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and Nanovibronix (NASDAQ:FEED) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

: IRIDEX has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.
: IRIDEX has higher revenue and earnings than Nanovibronix. IRIDEX is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IRIDEX $52.67M 0.35 -$4.44M -$0.26 N/A
Nanovibronix $2.55M 1.78 -$18.18M -$41.74 N/A
: 20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 8.6% of IRIDEX shares are owned by company insiders. Comparatively, 5.2% of Nanovibronix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: IRIDEX currently has a consensus price target of $3.00, indicating a potential upside of 185.71%. Given IRIDEX's stronger consensus rating and higher probable upside, analysts plainly believe IRIDEX is more favorable than Nanovibronix.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IRIDEX
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Nanovibronix
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: IRIDEX has a net margin of -8.42% compared to Nanovibronix's net margin of -712.30%. Nanovibronix's return on equity of -47.82% beat IRIDEX's return on equity.
Company Net Margins Return on Equity Return on Assets
IRIDEX -8.42% -1,204.74% -14.39%
Nanovibronix -712.30% -47.82% -38.06%
: In the previous week, IRIDEX and IRIDEX both had 1 articles in the media. IRIDEX's average media sentiment score of 0.00 equaled Nanovibronix'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IRIDEX
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nanovibronix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.35	-$4.44M	-$0.26	N/A
Nanovibronix	$2.55M	1.78	-$18.18M	-$41.74	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-8.42%	-1,204.74%	-14.39%
Nanovibronix	-712.30%	-47.82%	-38.06%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IRIDEX	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanovibronix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

IRIDEX beats Nanovibronix on 10 of the 14 factors compared between the two stocks.

How does Nanovibronix compare to Jin Medical International?

Nanovibronix (NASDAQ:FEED) and Jin Medical International (NASDAQ:ZJYL) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanovibronix
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Jin Medical International
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Nanovibronix had 1 more articles in the media than Jin Medical International. MarketBeat recorded 1 mentions for Nanovibronix and 0 mentions for Jin Medical International. Nanovibronix's average media sentiment score of 0.00 equaled Jin Medical International'saverage media sentiment score.
Company Overall Sentiment
Nanovibronix Neutral
Jin Medical International Neutral
: Jin Medical International has a net margin of 0.00% compared to Nanovibronix's net margin of -712.30%. Jin Medical International's return on equity of 0.00% beat Nanovibronix's return on equity.
Company Net Margins Return on Equity Return on Assets
Nanovibronix -712.30% -47.82% -38.06%
Jin Medical International N/A N/A N/A
: Nanovibronix has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Jin Medical International has a beta of 7.52, indicating that its share price is 652% more volatile than the S&P 500.
: Jin Medical International has higher revenue and earnings than Nanovibronix.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nanovibronix $2.55M 1.78 -$18.18M -$41.74 N/A
Jin Medical International $20.69M 0.91 $1.19M N/A N/A
: 16.4% of Nanovibronix shares are owned by institutional investors. 5.2% of Nanovibronix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Nanovibronix	Neutral
Jin Medical International	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-712.30%	-47.82%	-38.06%
Jin Medical International	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	1.78	-$18.18M	-$41.74	N/A
Jin Medical International	$20.69M	0.91	$1.19M	N/A	N/A

Summary

Jin Medical International beats Nanovibronix on 6 of the 10 factors compared between the two stocks.

How does Nanovibronix compare to SurgePays?

Nanovibronix (NASDAQ:FEED) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

: SurgePays has a consensus price target of $5.00, indicating a potential upside of 816.93%. Given SurgePays' stronger consensus rating and higher possible upside, analysts clearly believe SurgePays is more favorable than Nanovibronix.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanovibronix
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
SurgePays
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Nanovibronix and Nanovibronix both had 1 articles in the media. SurgePays' average media sentiment score of 0.50 beat Nanovibronix's score of 0.00 indicating that SurgePays is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nanovibronix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
SurgePays
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: SurgePays has a net margin of -63.32% compared to Nanovibronix's net margin of -712.30%. Nanovibronix's return on equity of -47.82% beat SurgePays' return on equity.
Company Net Margins Return on Equity Return on Assets
Nanovibronix -712.30% -47.82% -38.06%
SurgePays -63.32% -967.32% -241.91%
: Nanovibronix has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, SurgePays has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.
: Nanovibronix has higher earnings, but lower revenue than SurgePays. SurgePays is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nanovibronix $2.55M 1.78 -$18.18M -$41.74 N/A
SurgePays $56.96M 0.24 -$36.07M -$1.81 N/A
: 16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 6.9% of SurgePays shares are owned by institutional investors. 5.2% of Nanovibronix shares are owned by company insiders. Comparatively, 30.5% of SurgePays shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SurgePays	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanovibronix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SurgePays	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-712.30%	-47.82%	-38.06%
SurgePays	-63.32%	-967.32%	-241.91%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	1.78	-$18.18M	-$41.74	N/A
SurgePays	$56.96M	0.24	-$36.07M	-$1.81	N/A

Summary

SurgePays beats Nanovibronix on 8 of the 15 factors compared between the two stocks.

How does Nanovibronix compare to SeaStar Medical?

Nanovibronix (NASDAQ:FEED) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

: 16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are held by institutional investors. 5.2% of Nanovibronix shares are held by insiders. Comparatively, 0.7% of SeaStar Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Nanovibronix has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500.
: In the previous week, Nanovibronix had 1 more articles in the media than SeaStar Medical. MarketBeat recorded 1 mentions for Nanovibronix and 0 mentions for SeaStar Medical. Nanovibronix's average media sentiment score of 0.00 equaled SeaStar Medical'saverage media sentiment score.
Company Overall Sentiment
Nanovibronix Neutral
SeaStar Medical Neutral
: SeaStar Medical has a consensus price target of $6.00, suggesting a potential upside of 35.75%. Given SeaStar Medical's higher probable upside, analysts plainly believe SeaStar Medical is more favorable than Nanovibronix.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanovibronix
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
SeaStar Medical
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: SeaStar Medical has lower revenue, but higher earnings than Nanovibronix. SeaStar Medical is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nanovibronix $2.55M 1.78 -$18.18M -$41.74 N/A
SeaStar Medical $1.23M 14.37 -$12.15M -$8.30 N/A
: Nanovibronix has a net margin of -712.30% compared to SeaStar Medical's net margin of -984.60%. Nanovibronix's return on equity of -47.82% beat SeaStar Medical's return on equity.
Company Net Margins Return on Equity Return on Assets
Nanovibronix -712.30% -47.82% -38.06%
SeaStar Medical -984.60% -188.47% -106.42%

Company	Overall Sentiment
Nanovibronix	Neutral
SeaStar Medical	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	1.78	-$18.18M	-$41.74	N/A
SeaStar Medical	$1.23M	14.37	-$12.15M	-$8.30	N/A

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-712.30%	-47.82%	-38.06%
SeaStar Medical	-984.60%	-188.47%	-106.42%

Summary

Nanovibronix beats SeaStar Medical on 9 of the 13 factors compared between the two stocks.

How does Nanovibronix compare to OSR?

Nanovibronix (NASDAQ:FEED) and OSR (NASDAQ:OSRH) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

: In the previous week, OSR had 1 more articles in the media than Nanovibronix. MarketBeat recorded 2 mentions for OSR and 1 mentions for Nanovibronix. Nanovibronix's average media sentiment score of 0.00 equaled OSR'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nanovibronix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
OSR
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Nanovibronix has higher earnings, but lower revenue than OSR. OSR is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nanovibronix $2.55M 1.78 -$18.18M -$41.74 N/A
OSR $2.91M 5.90 -$27.06M -$1.28 N/A
: OSR has a net margin of -619.82% compared to Nanovibronix's net margin of -712.30%. OSR's return on equity of -13.53% beat Nanovibronix's return on equity.
Company Net Margins Return on Equity Return on Assets
Nanovibronix -712.30% -47.82% -38.06%
OSR -619.82% -13.53% -10.17%
: Nanovibronix has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, OSR has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanovibronix
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
OSR
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: 16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 5.2% of Nanovibronix shares are held by insiders. Comparatively, 60.6% of OSR shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanovibronix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OSR	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	1.78	-$18.18M	-$41.74	N/A
OSR	$2.91M	5.90	-$27.06M	-$1.28	N/A

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-712.30%	-47.82%	-38.06%
OSR	-619.82%	-13.53%	-10.17%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

OSR beats Nanovibronix on 9 of the 12 factors compared between the two stocks.

Get Nanovibronix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEED vs. The Competition

Export

Metric	Nanovibronix	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$4.22M	$3.77B	$4.22B	$11.77B
Dividend Yield	N/A	N/A	5.87%	5.26%
P/E Ratio	-0.03	4.05	23.37	27.07
Price / Sales	1.78	346.94	155.53	73.43
Price / Cash	N/A	3.94	52.08	53.90
Price / Book	0.04	3.81	37.87	6.69
Net Income	-$18.18M	-$76.79M	$114.66M	$332.64M
7 Day Performance	-1.60%	-0.64%	1.21%	2.01%
1 Month Performance	-37.24%	-2.29%	5.50%	9.19%
1 Year Performance	N/A	52.89%	18.68%	39.59%

Nanovibronix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEED Nanovibronix	0.0872 of 5 stars	$1.23 +7.9%	N/A	N/A	$4.22M	$2.55M	N/A	20
IRIX IRIDEX	1.6403 of 5 stars	$1.03 -1.0%	$3.00 +191.3%	N/A	$17.92M	$52.67M	N/A	120	News Coverage Upcoming Earnings Analyst Upgrade Gap Down
ZJYL Jin Medical International	N/A	$2.11 -8.3%	N/A	N/A	$16.52M	$20.69M	N/A	245	Gap Down
SURG SurgePays	1.8324 of 5 stars	$0.64 +3.5%	$5.00 +687.0%	N/A	$15.96M	$56.96M	N/A	40	Upcoming Earnings Gap Up
ICU SeaStar Medical	1.5098 of 5 stars	$3.87 -1.3%	$6.00 +55.0%	N/A	$15.44M	$1.23M	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEED) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanovibronix (FEED) Competitors

FEED vs. IRIX, ZJYL, SURG, ICU, and OSRH

How does Nanovibronix compare to IRIDEX?

Summary

How does Nanovibronix compare to Jin Medical International?

Summary

How does Nanovibronix compare to SurgePays?

Summary

How does Nanovibronix compare to SeaStar Medical?

Summary

How does Nanovibronix compare to OSR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanovibronix (FEED) Competitors

FEED vs. IRIX, ZJYL, SURG, ICU, and OSRH

How does Nanovibronix compare to IRIDEX?

Summary

How does Nanovibronix compare to Jin Medical International?

Summary

How does Nanovibronix compare to SurgePays?

Summary

How does Nanovibronix compare to SeaStar Medical?

Summary

How does Nanovibronix compare to OSR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEED vs. The Competition

Nanovibronix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools